Vertex Pharmaceuticals
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading lower after Q3 earnings missed ...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The ...
Latest News
17 hours ago · seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 TranscriptVertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Global Biopharma Conference 2026 Transcript
5 days ago · zacks.com
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to KnowVertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
14 days ago · zacks.com
VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View RaisedVertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
14 days ago · seekingalpha.com
Vertex Pharmaceuticals Incorporated (VRTX) Q3 2026 Earnings Call TranscriptVertex Pharmaceuticals Incorporated ( VRTX ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Susie Lisa - Senior Vice President of Investor Relations Reshma Kewalramani - CEO, President & Director Duncan J. McKechnie - Executive VP & Chief Commercial Officer Charles Wagner - Executive VP, COO & CFO Conference Call Participants Cory Kasimov - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Salveen Richter - Goldman Sachs Group, Inc., Research Division Geoffrey Meacham - Citigroup Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research Brian Abrahams - RBC Capital Markets, Research Division Michael Yee - UBS Investment Bank, Research Division Tazeen Ahmad - BofA Securities, Research Division Akash Tewari - Jefferies LLC, Research Division Terence Flynn - Morgan Stanley, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Presentation Operator Good day, and welcome to the Vertex Pharmaceuticals Third Quarter 2026 Earnings Call.
14 days ago · zacks.com
Vertex (VRTX) Q3 Earnings: Taking a Look at Key Metrics Versus EstimatesWhile the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
14 days ago · zacks.com
Vertex Pharmaceuticals (VRTX) Misses Q3 Earnings EstimatesVertex Pharmaceuticals (VRTX) came out with quarterly earnings of $4.76 per share, missing the Zacks Consensus Estimate of $4.92 per share. This compares to earnings of $4.8 per share a year ago.
20 days ago · zacks.com
Ahead of Vertex (VRTX) Q3 Earnings: Get Ready With Wall Street Estimates for Key MetricsEvaluate the expected performance of Vertex (VRTX) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
20 days ago · zacks.com
Here is What to Know Beyond Why Vertex Pharmaceuticals Incorporated (VRTX) is a Trending StockRecently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
21 days ago · zacks.com
Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: Here's WhyIn the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $517.49, denoting a -1.23% move from the preceding trading day.
22 days ago · zacks.com
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy?Vertex (VRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove VRTX